FY2024 Earnings Forecast for Affimed Issued By HC Wainwright

Affimed (NASDAQ:AFMD) – Research analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Affimed in a report issued on Wednesday, December 18th. HC Wainwright analyst S. Ramakanth now anticipates that the biopharmaceutical company will post earnings of ($4.28) per share for the year, up from their prior forecast of ($4.31). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share. HC Wainwright also issued estimates for Affimed’s Q4 2024 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($3.02) EPS.

Several other equities research analysts have also weighed in on AFMD. Stifel Nicolaus dropped their target price on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. Finally, Wells Fargo & Company decreased their target price on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Stock Performance

NASDAQ:AFMD opened at $1.19 on Monday. The business has a 50 day simple moving average of $2.88 and a 200 day simple moving average of $3.98. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. Affimed has a 12-month low of $1.14 and a 12-month high of $8.95.

Institutional Investors Weigh In On Affimed

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in Affimed in the 3rd quarter valued at about $44,000. Choreo LLC acquired a new stake in shares of Affimed in the 2nd quarter worth approximately $54,000. FMR LLC lifted its stake in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Intellectus Partners LLC increased its stake in shares of Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 10,250 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the period. 30.82% of the stock is currently owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.